Adjuvant therapy for high-risk uveal melanoma
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have high-risk non-metastatic uveal melanoma (stage II or III).
- You have completed primary local therapy (e.g., radiation or surgery) within the past 120 days.
- You have not had systemic treatment for uveal melanoma before.
- You have no evidence of metastatic disease.
- You have adequate organ function and are willing to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called darovasertib given before standard surgery for primary uveal melanoma (a type of eye cancer that hasn't spread). The goal is to see if the drug can shrink the tumor and improve outcomes.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
This trial tests whether an injected medicine placed directly into melanoma tumors before surgery can improve outcomes for melanoma that has spread to nearby lymph nodes/skin but can still be fully removed. It aims to shrink the cancer and reduce the chance it comes back after surgery.
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.